Home › Companies › BEAM THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BEAM THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2025: 5 items on BEAM THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 3 elected · 2 approved.
Notable dissent: 1 director (14.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BEAM THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are BEAM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark Fishman, M.D. | 61,949,019 | 10,285,110 | 63,755 | -- | 12,201,172 | 86% | Elected | — |
| Elect Director: Carole Ho, M.D. | 71,720,651 | 548,021 | 29,212 | -- | 12,201,172 | 99.2% | Elected | — |
| Elect Director: Kathleen Walsh | 71,888,413 | 379,636 | 29,835 | -- | 12,201,172 | 99.5% | Elected | — |
| 2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 | 84,281,031 | 154,426 | 63,599 | -- | -- | 99.8% | Approved | — |
| 3. Compensation of the Company's named executive officers | 71,701,062 | 562,871 | 33,951 | -- | 12,201,172 | 99.2% | Approved | — |
Source: BEAM THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
277 asset managers disclosed a vote on at least one BEAM THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Carole Ho, M.D.
BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carole Ho, M.D.”): 71,720,651 for, 548,021 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 29,460,705 for, 126,726 against, 5,512 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,716,828 | 0 | 0 | 0 | For |
| ARK ETF Trust | 7,995,179 | 0 | 0 | 0 | For |
| Fidelity | 4,653,310 | 0 | 0 | 0 | For |
| BlackRock | 2,784,446 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,272,505 | 0 | 0 | 0 | For |
| Charles Schwab | 783,402 | 0 | 0 | 0 | For |
| Equitable | 185,069 | 86,610 | 0 | 0 | Mixed |
| JPMorgan | 240,632 | 0 | 0 | 0 | For |
| TIAA | 196,720 | 0 | 0 | 0 | For |
| State Street | 181,385 | 0 | 0 | 0 | For |
| Global X | 141,913 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 132,736 | 0 | 0 | 0 | For |
| Pacific Life | 130,302 | 0 | 0 | 0 | For |
| Lincoln Financial | 99,381 | 3,184 | 0 | 0 | For |
| American Century | 99,408 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,817 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 69,058 | 0 | 0 | 0 | For |
| John Hancock | 60,077 | 0 | 0 | 0 | For |
| Transamerica | 55,500 | 0 | 0 | 0 | For |
| MFS | 55,346 | 0 | 0 | 0 | For |
| Northern Trust | 54,062 | 0 | 0 | 0 | For |
| WisdomTree | 51,544 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,557 | 0 | 0 | 0 | For |
| ProShares | 45,776 | 0 | 0 | 0 | For |
| Brighthouse | 44,519 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Kathleen Walsh
BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathleen Walsh”): 71,888,413 for, 379,636 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 29,460,705 for, 126,726 against, 5,512 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,716,828 | 0 | 0 | 0 | For |
| ARK ETF Trust | 7,995,179 | 0 | 0 | 0 | For |
| Fidelity | 4,653,310 | 0 | 0 | 0 | For |
| BlackRock | 2,784,446 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,272,505 | 0 | 0 | 0 | For |
| Charles Schwab | 783,402 | 0 | 0 | 0 | For |
| Equitable | 185,069 | 86,610 | 0 | 0 | Mixed |
| JPMorgan | 240,632 | 0 | 0 | 0 | For |
| TIAA | 196,720 | 0 | 0 | 0 | For |
| State Street | 181,385 | 0 | 0 | 0 | For |
| Global X | 141,913 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 132,736 | 0 | 0 | 0 | For |
| Pacific Life | 130,302 | 0 | 0 | 0 | For |
| Lincoln Financial | 99,381 | 3,184 | 0 | 0 | For |
| American Century | 99,408 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,817 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 69,058 | 0 | 0 | 0 | For |
| John Hancock | 60,077 | 0 | 0 | 0 | For |
| Transamerica | 55,500 | 0 | 0 | 0 | For |
| MFS | 55,346 | 0 | 0 | 0 | For |
| Northern Trust | 54,062 | 0 | 0 | 0 | For |
| WisdomTree | 51,544 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,557 | 0 | 0 | 0 | For |
| ProShares | 45,776 | 0 | 0 | 0 | For |
| Brighthouse | 44,519 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Mark Fishman, M.D.
BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Fishman, M.D.”): 61,949,019 for, 10,285,110 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 28,771,445 for, 815,986 against, 5,512 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,716,066 | 762 | 0 | 0 | For |
| ARK ETF Trust | 7,995,179 | 0 | 0 | 0 | For |
| Fidelity | 4,653,310 | 0 | 0 | 0 | For |
| BlackRock | 2,784,446 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,272,505 | 0 | 0 | 0 | For |
| Charles Schwab | 783,402 | 0 | 0 | 0 | For |
| Equitable | 185,069 | 86,610 | 0 | 0 | Mixed |
| JPMorgan | 240,632 | 0 | 0 | 0 | For |
| TIAA | 196,720 | 0 | 0 | 0 | For |
| State Street | 181,213 | 172 | 0 | 0 | For |
| Global X | 141,913 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 132,736 | 0 | 0 | Against |
| Pacific Life | 130,302 | 0 | 0 | 0 | For |
| Lincoln Financial | 86,221 | 16,344 | 0 | 0 | Mixed |
| American Century | 0 | 99,408 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 80,817 | 0 | 0 | Against |
| Yiheng Capital Management, L.P. | 69,058 | 0 | 0 | 0 | For |
| John Hancock | 27,958 | 32,119 | 0 | 0 | Mixed |
| Transamerica | 55,500 | 0 | 0 | 0 | For |
| MFS | 0 | 55,346 | 0 | 0 | Against |
| Northern Trust | 0 | 54,062 | 0 | 0 | Against |
| WisdomTree | 0 | 51,544 | 0 | 0 | Against |
| Bridge Builder Trust | 42,882 | 7,675 | 0 | 0 | Mixed |
| ProShares | 0 | 45,776 | 0 | 0 | Against |
| Brighthouse | 44,518 | 1 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.
BEAM THERAPEUTICS INC.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 71,701,062 for, 562,871 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,716,828 | 0 | 0 | 0 | For |
| ARK ETF Trust | 7,995,179 | 0 | 0 | 0 | For |
| Fidelity | 4,653,310 | 0 | 0 | 0 | For |
| BlackRock | 2,784,446 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,272,505 | 0 | 0 | 0 | For |
| Charles Schwab | 783,402 | 0 | 0 | 0 | For |
| Equitable | 271,679 | 0 | 0 | 0 | For |
| JPMorgan | 240,632 | 0 | 0 | 0 | For |
| TIAA | 196,720 | 0 | 0 | 0 | For |
| State Street | 181,379 | 6 | 0 | 0 | For |
| Global X | 141,913 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 132,736 | 0 | 0 | 0 | For |
| Pacific Life | 130,302 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,565 | 0 | 0 | 0 | For |
| American Century | 99,408 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,817 | 0 | 0 | 0 | For |
| John Hancock | 60,077 | 0 | 0 | 0 | For |
| Transamerica | 55,500 | 0 | 0 | 0 | For |
| MFS | 55,346 | 0 | 0 | 0 | For |
| Northern Trust | 54,062 | 0 | 0 | 0 | For |
| WisdomTree | 51,544 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,882 | 7,675 | 0 | 0 | Mixed |
| ProShares | 45,776 | 0 | 0 | 0 | For |
| Brighthouse | 44,519 | 0 | 0 | 0 | For |
| ARK Venture Fund | 36,860 | 0 | 0 | 0 | For |
Fund voting reports, all 63 managers: 29,510,002 for, 8,371 against, 5,512 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 8,056,102 | 0 | 0 | 0 | For |
| Fidelity | 4,952,230 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 4,540,132 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 4,433,768 | 0 | 0 | 0 | For |
| BlackRock | 2,909,856 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,832,540 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,954,882 | 0 | 0 | 0 | For |
| Temasek Holdings (Private) Ltd | 1,812,972 | 0 | 0 | 0 | For |
| State Street | 1,546,507 | 7,495 | 0 | 0 | For |
| Redmile Group, LLC | 1,527,342 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,139,443 | 0 | 0 | 0 | For |
| Charles Schwab | 783,595 | 0 | 0 | 0 | For |
| Woodline Partners LP | 760,611 | 0 | 0 | 0 | For |
| JPMorgan | 680,573 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 559,517 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 526,685 | 0 | 0 | 0 | For |
| Northern Trust | 434,943 | 0 | 0 | 0 | For |
| Janus Henderson | 433,883 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 424,248 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 291,041 | Withhold |
| Vanguard | 259,311 | 0 | 0 | 0 | For |
| Citadel | 226,406 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 209,642 | 0 | 0 | 0 | For |
| Casdin Capital, LLC | 201,205 | 0 | 0 | 0 | For |
| Nuveen | 199,880 | 0 | 0 | 0 | For |
Institutional-manager reports, all 228 managers: 44,280,209 for, 317,520 against, 291,041 withheld, 1,384 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Approved · of votes cast
Description as filed by funds: RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.
BEAM THERAPEUTICS INC.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025”): 84,281,031 for, 154,426 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 29,586,741 for, 690 against, 5,512 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,716,828 | 0 | 0 | 0 | For |
| ARK ETF Trust | 7,995,179 | 0 | 0 | 0 | For |
| Fidelity | 4,653,310 | 0 | 0 | 0 | For |
| BlackRock | 2,784,446 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,272,505 | 0 | 0 | 0 | For |
| Charles Schwab | 783,402 | 0 | 0 | 0 | For |
| Equitable | 271,679 | 0 | 0 | 0 | For |
| JPMorgan | 240,632 | 0 | 0 | 0 | For |
| TIAA | 196,720 | 0 | 0 | 0 | For |
| State Street | 181,385 | 0 | 0 | 0 | For |
| Global X | 141,913 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 132,736 | 0 | 0 | 0 | For |
| Pacific Life | 130,302 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,565 | 0 | 0 | 0 | For |
| American Century | 99,408 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,817 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 69,058 | 0 | 0 | 0 | For |
| John Hancock | 60,077 | 0 | 0 | 0 | For |
| Transamerica | 55,500 | 0 | 0 | 0 | For |
| MFS | 55,346 | 0 | 0 | 0 | For |
| Northern Trust | 54,062 | 0 | 0 | 0 | For |
| WisdomTree | 51,544 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,557 | 0 | 0 | 0 | For |
| ProShares | 45,776 | 0 | 0 | 0 | For |
| Brighthouse | 44,519 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 100,557,094 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.67% |
| 2 | ARK ETF Trust | 7.95% |
| 3 | Fidelity | 4.63% |
| 4 | BlackRock | 2.77% |
| 5 | T. Rowe Price | 2.26% |
| 6 | Charles Schwab | 0.78% |
| 7 | Equitable | 0.27% |
| 8 | JPMorgan | 0.24% |
| 9 | TIAA | 0.20% |
| 10 | State Street | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 8.01% |
| 2 | Fidelity | 4.92% |
| 3 | ARCH Venture Management, LLC | 4.51% |
| 4 | Nikko Asset Management Co., Ltd. | 4.41% |
| 5 | BlackRock | 2.89% |
| 6 | T. Rowe Price | 2.82% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.94% |
| 8 | Temasek Holdings (Private) Ltd | 1.80% |
| 9 | State Street | 1.55% |
| 10 | Redmile Group, LLC | 1.52% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| ARK Investment Management LLC | 12,467,189 | 12.40% | Schedule 13G, filed February 3, 2026 |
| FMR LLC and affiliates | 10,042,092 | 9.99% | Proxy statement (DEF 14A), proxy filed April 18, 2025 |
| Farallon Partners, L.L.C. | 9,808,603 | 9.75% | Schedule 13G, filed February 5, 2026 |
| Farallon Capital Partners and affiliates | 9,644,111 | 9.59% | Proxy statement (DEF 14A), proxy filed April 18, 2025 |
| Vanguard Group | 8,871,292 | 8.82% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 8,102,656 | 8.06% | Form 13F, quarter ended March 31, 2025 |
| FMR (Fidelity) | 7,920,053 | 7.88% | Form 13F, quarter ended March 31, 2025 |
| State Street | 3,440,119 | 3.42% | Form 13F, quarter ended March 31, 2025 |
| T. Rowe Price | 3,026,701 | 3.01% | Form 13F, quarter ended March 31, 2025 |
| Citadel Advisors | 2,701,747 | 2.69% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 100,557,094 shares outstanding, as reported by BEAM THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BEAM THERAPEUTICS INC.'s shareholder meeting held June 4, 2025, in the 2024-2025 proxy season, 277 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,408 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — BEAM THERAPEUTICS INC.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BEAM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BEAM THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BEAM THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “BEAM THERAPEUTICS (BEAM) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/beam-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.